Cargando…

Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study

The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events and studies on APS-related obstetric manifestations are scar...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Barrio-Longarela, Sara, Martínez-Taboada, Víctor M., Blanco-Olavarri, Pedro, Merino, Ana, Riancho-Zarrabeitia, Leyre, Comins-Boo, Alejandra, López-Hoyos, Marcos, Hernández, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464174/
https://www.ncbi.nlm.nih.gov/pubmed/34910282
http://dx.doi.org/10.1007/s12016-021-08915-9
_version_ 1784787525156470784
author Del Barrio-Longarela, Sara
Martínez-Taboada, Víctor M.
Blanco-Olavarri, Pedro
Merino, Ana
Riancho-Zarrabeitia, Leyre
Comins-Boo, Alejandra
López-Hoyos, Marcos
Hernández, José L.
author_facet Del Barrio-Longarela, Sara
Martínez-Taboada, Víctor M.
Blanco-Olavarri, Pedro
Merino, Ana
Riancho-Zarrabeitia, Leyre
Comins-Boo, Alejandra
López-Hoyos, Marcos
Hernández, José L.
author_sort Del Barrio-Longarela, Sara
collection PubMed
description The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events and studies on APS-related obstetric manifestations are scarce. Furthermore, the majority of them included patients with positive aPL and different autoimmune diseases. Here, we assess the utility of aGAPSS to predict the response to treatment in aPL carriers without other autoimmune disorders. One-hundred and thirty-seven women with aPL ever pregnant were included. Sixty-five meet the APS classification criteria, 61 had APS-related obstetric manifestations, and 11 were asymptomatic carriers. The patients’ aGAPSS risk was grouped as low (< 6, N = 73), medium (6–11, N = 40), and high risk (≥ 12, N = 24). Since vascular risk factors included in the aGAPSS were infrequent in this population (< 10%), the aGAPSS score was mainly determined by the aPL profile. Overall, the live birth rate was 75%, and 37.2% of the patients had at least one adverse pregnancy outcome (APO). When considering patients according to the aGAPSS (high, medium, and low risk), no significant differences were found for pregnancy loss (29.2%, 25%, and 21.9%) or APO (33.3%, 47.5%, and 32.9%). In the present study, including aPL carriers without other autoimmune diseases, aGAPSS is not a valuable tool to identify patients at risk for obstetric complications despite treatment. In these patients with gestational desire, in addition to the aPL profile, other pregnancy-specific factors, such as age or previous obstetric history, should be considered.
format Online
Article
Text
id pubmed-9464174
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94641742022-09-12 Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study Del Barrio-Longarela, Sara Martínez-Taboada, Víctor M. Blanco-Olavarri, Pedro Merino, Ana Riancho-Zarrabeitia, Leyre Comins-Boo, Alejandra López-Hoyos, Marcos Hernández, José L. Clin Rev Allergy Immunol Article The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events and studies on APS-related obstetric manifestations are scarce. Furthermore, the majority of them included patients with positive aPL and different autoimmune diseases. Here, we assess the utility of aGAPSS to predict the response to treatment in aPL carriers without other autoimmune disorders. One-hundred and thirty-seven women with aPL ever pregnant were included. Sixty-five meet the APS classification criteria, 61 had APS-related obstetric manifestations, and 11 were asymptomatic carriers. The patients’ aGAPSS risk was grouped as low (< 6, N = 73), medium (6–11, N = 40), and high risk (≥ 12, N = 24). Since vascular risk factors included in the aGAPSS were infrequent in this population (< 10%), the aGAPSS score was mainly determined by the aPL profile. Overall, the live birth rate was 75%, and 37.2% of the patients had at least one adverse pregnancy outcome (APO). When considering patients according to the aGAPSS (high, medium, and low risk), no significant differences were found for pregnancy loss (29.2%, 25%, and 21.9%) or APO (33.3%, 47.5%, and 32.9%). In the present study, including aPL carriers without other autoimmune diseases, aGAPSS is not a valuable tool to identify patients at risk for obstetric complications despite treatment. In these patients with gestational desire, in addition to the aPL profile, other pregnancy-specific factors, such as age or previous obstetric history, should be considered. Springer US 2021-12-15 2022 /pmc/articles/PMC9464174/ /pubmed/34910282 http://dx.doi.org/10.1007/s12016-021-08915-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Del Barrio-Longarela, Sara
Martínez-Taboada, Víctor M.
Blanco-Olavarri, Pedro
Merino, Ana
Riancho-Zarrabeitia, Leyre
Comins-Boo, Alejandra
López-Hoyos, Marcos
Hernández, José L.
Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title_full Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title_fullStr Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title_full_unstemmed Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title_short Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
title_sort does adjusted global antiphospholipid syndrome score (agapss) predict the obstetric outcome in antiphospholipid antibody carriers? a single-center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464174/
https://www.ncbi.nlm.nih.gov/pubmed/34910282
http://dx.doi.org/10.1007/s12016-021-08915-9
work_keys_str_mv AT delbarriolongarelasara doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT martineztaboadavictorm doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT blancoolavarripedro doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT merinoana doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT rianchozarrabeitialeyre doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT cominsbooalejandra doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT lopezhoyosmarcos doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy
AT hernandezjosel doesadjustedglobalantiphospholipidsyndromescoreagapsspredicttheobstetricoutcomeinantiphospholipidantibodycarriersasinglecenterstudy